Zentalis Pharmaceuticals (ZNTL)
Develops azenosertib for biomarker-selected platinum-resistant ovarian cancer.
$3.84
Pre-market+0.06 (+1.59%)
At close$3.78(+1.89%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions104 holders · as of Mar 31, 2026 | 60.78% | 43.56M shares | |
| Insiders11 holders · as of Jun 18, 2026 | 4.63% | 3.32M shares | |
| Strategic holders2 holders · as of Aug 19, 2026 | 30.41% | 21.79M shares | |
| Otherremainder | 4.18% | 3.00M shares |
71.67M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
104 holders · 43.56M shares · 27 new positions · 57 increased · 27 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| 5Am Venture Management, LLC | 3.95M | 5.51% | 0 | May 15, 2026 |
| Squadron Capital Management LLC | 3.63M | 5.07% | +3.63Mnew | May 15, 2026 |
| Two Sigma Investments, LP | 2.96M | 4.13% | +1.49M | May 15, 2026 |
| Acadian Asset Management LLC | 2.85M | 3.97% | −1.0K | May 13, 2026 |
| Vanguard Capital Management LLC | 2.31M | 3.22% | +2.31Mnew | May 15, 2026 |
| Renaissance Technologies LLC | 1.94M | 2.70% | −945.6K | May 14, 2026 |
| Citadel Advisors LLC | 1.73M | 2.42% | −232.2K | May 15, 2026 |
| D. E. Shaw & Co., Inc. | 1.48M | 2.07% | −176.3K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Walters William T | 19.70% | 13.51M | 13G | Jan 5, 2026 ↗ |
| FMR LLCincl. Abigail P. Johnson | 7.14% | 5.08M | Oct 7, 2024 ↗ | |
| Barclays PLC | 5.32% | 3.84M | 13G | Nov 12, 2025 ↗ |
| BlackRock, Inc. | 5.20% | 3.71M | 13G | Jul 30, 2026 ↗ |
| 5AM Opportunities II (GP), LLC | 5.20% | 3.95M | 13G | Dec 30, 2025 ↗ |
| Squadron Master Fund LP | 5.10% | 3.68M | 13G | Mar 3, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Walters Group10 percent owner | Purchase | 4,335,000 | $3.50 | 17,844,973 |
| Feb 9, 2026 | Julia Marie Eastlanddirector, officer: CEO & President | Sale | 889 | $2.39 | 79,133 |
| Feb 6, 2026 | Julia Marie Eastlanddirector, officer: CEO & President | Sale | 7,866 | $2.43 | 80,022 |
| Feb 10, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 6,894 | $2.42 | 146,506 |
| Feb 9, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 3,379 | $2.39 | 153,400 |
| Feb 6, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 29,951 | $2.43 | 156,779 |
| Feb 9, 2026 | Ingmar Brunsofficer: Chief Medical Officer | Sale | 335 | $2.39 | 33,332 |
| Feb 6, 2026 | Ingmar Brunsofficer: Chief Medical Officer | Sale | 2,962 | $2.43 | 33,667 |
| Feb 3, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 556 | $2.52 | 186,730 |
| Feb 2, 2026 | Vincent Vultaggioofficer: PAO and PFO | Sale | 2,540 | $2.55 | 187,286 |
CongressHouse and Senate disclosures
Not reported.